Sanara MedTech (SMTI)
NASDAQ:SMTI
Want to see SMTI full AI Analyst Report?
SMTI Stock Chart & Stats
$29.52
$0.13(0.40%)
At close: 4:00 PM EST
$29.52
$0.13(0.40%)
Day’s Range― - ―
52-Week Range$16.05 - $35.95
Previous CloseN/A
Volume5.72K
Average Volume (3M)61.65K
Market Cap
$176.19M
Enterprise Value$207.80M
Total Cash (Recent Filing)$16.58M
Total Debt (Recent Filing)$48.19M
Price to Earnings (P/E)―
Beta1.38
Next Earnings
May 12, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding9,167,040
10 Day Avg. Volume48,775
30 Day Avg. Volume61,645
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)33.96
Price to Sales (P/S)1.95
P/FCF Ratio93.17
Enterprise Value/Market Cap1.18
Enterprise Value/Revenue2.02
Enterprise Value/Gross Profit2.24
Enterprise Value/Ebitda17.60
Forecast
1Y Price Target
$34.00Price Target Upside15.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.16
Revenue Forecast (FY)$118.60M
Bulls Say, Bears Say
Bulls Say
Commercial PartnershipVizient contract expands institutional access to BIASURGE through contracted pricing and pre-negotiated terms, supporting potential revenue acceleration as hospitals adopt the product.
Pipeline Differentiation And Regulatory ProgressOsStic's Breakthrough Device designation and preclinical data showing stronger bonding than traditional bone cement position it as a differentiated bone bioadhesive with potential to expand the company's addressable market.
Strategic Refocus And Margin ProfileDiscontinuation of the loss-making THP unit refocuses the company on a higher-margin, scalable surgical platform, improving operational efficiency and potential profitability.
Bears Say
Balance Sheet LeverageModest cash balances alongside significant long-term debt indicate leverage that may constrain financial flexibility and limit the ability to fund growth initiatives.
Legacy Cash DragThe discontinued THP unit had been loss-making and consumed cash, creating a legacy drag that could pressure liquidity during the transition to a focused surgical business.
Refinancing And Interest-rate SensitivitySignificant long-term debt increases exposure to refinancing risk and sensitivity to higher interest costs, which could strain resources if commercial ramp-up is slower than expected.
Sanara MedTech News
SMTI FAQ
What was Sanara MedTech’s price range in the past 12 months?
Sanara MedTech lowest stock price was $16.05 and its highest was $35.95 in the past 12 months.
What is Sanara MedTech’s market cap?
Sanara MedTech’s market cap is $176.19M.
When is Sanara MedTech’s upcoming earnings report date?
Sanara MedTech’s upcoming earnings report date is May 12, 2026 which is in 14 days.
How were Sanara MedTech’s earnings last quarter?
Sanara MedTech released its earnings results on Mar 24, 2026. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of $0.11 by -$0.24.
Is Sanara MedTech overvalued?
According to Wall Street analysts Sanara MedTech’s price is currently Undervalued.
Does Sanara MedTech pay dividends?
Sanara MedTech does not currently pay dividends.
What is Sanara MedTech’s EPS estimate?
Sanara MedTech’s EPS estimate is -0.13.
How many shares outstanding does Sanara MedTech have?
Sanara MedTech has 9,167,040 shares outstanding.
What happened to Sanara MedTech’s price movement after its last earnings report?
Sanara MedTech reported an EPS of -$0.13 in its last earnings report, missing expectations of $0.11. Following the earnings report the stock price went down -1.418%.
Which hedge fund is a major shareholder of Sanara MedTech?
Currently, no hedge funds are holding shares in SMTI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sanara MedTech Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$34.00 (15.18% Upside)
$34.00 (15.18% Upside)
Blogger Sentiment
Bullish
SMTI Sentiment 70%
Sector Average 72%
Sector Average 72%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.65%
12-Months-Change
Fundamentals
Return on Equity
-178.57%
Trailing 12-Months
Asset Growth
-17.20%
Trailing 12-Months
Company Description
Sanara MedTech
Sanara MedTech Inc. (SMTI) is a medical technology company focused on developing and commercializing advanced wound care and regenerative medicine products. The company operates primarily in the healthcare sector, offering innovative solutions designed to improve patient outcomes and promote healing in chronic and acute wounds. Sanara's core product portfolio includes advanced wound dressings and bioactive solutions that utilize its proprietary technologies to facilitate tissue regeneration and healing processes.
SMTI Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights strong commercial momentum and meaningful financial improvement in 2025 — including record revenue, expanded gross margins, materially higher adjusted EBITDA, a positive operating cash flow turnaround, distributor and facility expansion, Vizient contract win, and clear R&D/IP progress. Near-term headwinds include a Q4 continuing-operations net loss, a noncash impairment charge, higher operating expenses driven by strategic investments, a sizable increase in long-term debt, and THP wind-down cash impacts. Management reiterated confident, externally provided guidance for 2026 and plans targeted investments (sales coverage expansion, R&D) to support growth. Overall, the positive operational and financial achievements, plus tangible growth catalysts, outweigh the listed challenges.View all SMTI earnings summariesSMTI Stock 12 Month Forecast
Average Price Target
$34.00
▲(15.18% Upside)
Technical Analysis
InfuSystem Holdings
―
Orasure Technologies
―
Stereotaxis
―
Utah Medical Products
―
Sharps Technology, Inc.
―
Ownership Overview
3.32% Insiders
2.80% Mutual Funds
1.70% Other Institutional Investors
89.04% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---